CLEVELAND — A modified form of vitamin B12 is showing early promise in the fight against glioblastoma, one of the deadliest and most treatment-resistant brain cancers. The research, published in the journal *Oncoscience*, centers on a compound called nitrosylcobalamin, or NO-Cbl. It is essentially vitamin B12 that has been altered to release nitric oxide.
For families facing a glioblastoma diagnosis, the stakes could not be higher. Even with surgery, radiation, and chemotherapy, patients typically survive less than 15 months.
The blood-brain barrier is a major reason why. This protective structure blocks most drugs from ever reaching tumor tissue in the brain. But the new study offers a different path.
Led by first and corresponding author Joseph A. Bauer of Nitric Oxide Services, LLC and the Cleveland Clinic Foundation Taussig Cancer Center, the team set out to see if NO-Cbl could cross that barrier and target glioblastoma tumors selectively.
They put the compound through a series of rigorous tests. The researchers used the NCI-60 human tumor cell line panel to measure activity against cancer cells. They conducted pharmacokinetic studies in rats that had glioblastoma tumors.
And they examined how NO-Cbl performed when combined with other treatments in human glioblastoma cell lines. The results were encouraging. NO-Cbl showed antitumor activity across a wide range of cancer types.
Tumor cells originating in the central nervous system displayed a moderate level of sensitivity to the treatment. What this means for patients is still early.
But any therapy that can cross the blood-brain barrier and reach the tumor is a step forward for a disease that has seen little improvement in survival for decades. The study also examined how NO-Cbl worked alongside other agents, including TRAIL and temozolomide, a standard chemotherapy for glioblastoma. The findings suggest potential for synergistic activity, meaning the combination could be more powerful than any single treatment alone.
Glioblastoma multiforme remains among the most lethal cancers of the brain. For the families who hear that diagnosis, every new avenue of research matters.
The next watch point will be whether these early results hold up in further testing. The study opens a door, but the road to a new therapy is long. Consult your doctor for medical advice.
